Prospective native coronary artery stenosis treated with sirolimus-eluting stent (ONASSIS) registry - Acute results and mid-term outcomes

A single-center experience

Vassilis Voudris, Elias Alexopoulos, Panagiotis Karyofillis, John Malakos, Athanasios Manginas, Constantinos Spargias, Gregory Pavlides, Sotirios Patsilinakos, Alexandros Anyfantakis, Dennis V. Cokkinos

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background. Encouraging results with the use of the sirolimus-eluting stent (SES) have been recently presented in several multicenter trials. In the present study, the short-and mid-term clinical outcomes of the SES in everyday clinical practice of interventional cardiology were compared with a strategy using conventional bare metal stents. Methods. In a total of 530 consecutive patients (males 86%, mean age 61 ± 10 years) who had been treated with a SES were compared with a control group of 398 patients (males 87%, mean age 59 ± 11 years) treated with a bare metal stent before the use of SES. In-hospital results and clinical outcomes during follow-up (11.22 ± 3.4 versus 11.41 ± 3.1 months) were obtained. Results. Patients treated with SES had more risk factors for coronary artery disease or multivessel disease compared to those with treated bare metal stent. The clinical success rate was 99.6% in the SES group and 98.5% in the bare metal stent group (p = ns), and non-Q-wave myocardial infarction (MI) occurred in 5.7% and 4.0% of patients, respectively. The incidence of death or MI during follow-up was not different (1.1% versus 1.3% and 0.8% versus 1.8%; p = ns). Percutaneous or surgical revascularization for target lesion restenosis was required in 2.1% of patients treated with SES and in 10.1% of those with bare metal stents (p < 0.001), and the event-free survival from death, cerebrovascular accident, MI or any percutaneous or surgical revascularization was 93.13% and 83.63%, respectively (p < 0.01). Conclusions. The implantation of the SES is associated with excellent in-hospital and mid-term results, mainly because of dramatic reductions in the need for repeat revascularization, despite a higher risk factor profile and more complex lesion characteristics.

Original languageEnglish (US)
Pages (from-to)401-405
Number of pages5
JournalJournal of Invasive Cardiology
Volume17
Issue number8
StatePublished - Aug 1 2005

Fingerprint

Coronary Stenosis
Sirolimus
Stents
Registries
Metals
Myocardial Infarction
Cardiology
Multicenter Studies
Disease-Free Survival
Coronary Artery Disease
Stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Voudris, V., Alexopoulos, E., Karyofillis, P., Malakos, J., Manginas, A., Spargias, C., ... Cokkinos, D. V. (2005). Prospective native coronary artery stenosis treated with sirolimus-eluting stent (ONASSIS) registry - Acute results and mid-term outcomes: A single-center experience. Journal of Invasive Cardiology, 17(8), 401-405.

Prospective native coronary artery stenosis treated with sirolimus-eluting stent (ONASSIS) registry - Acute results and mid-term outcomes : A single-center experience. / Voudris, Vassilis; Alexopoulos, Elias; Karyofillis, Panagiotis; Malakos, John; Manginas, Athanasios; Spargias, Constantinos; Pavlides, Gregory; Patsilinakos, Sotirios; Anyfantakis, Alexandros; Cokkinos, Dennis V.

In: Journal of Invasive Cardiology, Vol. 17, No. 8, 01.08.2005, p. 401-405.

Research output: Contribution to journalArticle

Voudris, V, Alexopoulos, E, Karyofillis, P, Malakos, J, Manginas, A, Spargias, C, Pavlides, G, Patsilinakos, S, Anyfantakis, A & Cokkinos, DV 2005, 'Prospective native coronary artery stenosis treated with sirolimus-eluting stent (ONASSIS) registry - Acute results and mid-term outcomes: A single-center experience', Journal of Invasive Cardiology, vol. 17, no. 8, pp. 401-405.
Voudris, Vassilis ; Alexopoulos, Elias ; Karyofillis, Panagiotis ; Malakos, John ; Manginas, Athanasios ; Spargias, Constantinos ; Pavlides, Gregory ; Patsilinakos, Sotirios ; Anyfantakis, Alexandros ; Cokkinos, Dennis V. / Prospective native coronary artery stenosis treated with sirolimus-eluting stent (ONASSIS) registry - Acute results and mid-term outcomes : A single-center experience. In: Journal of Invasive Cardiology. 2005 ; Vol. 17, No. 8. pp. 401-405.
@article{3fa10cf9a08a49d28fd08fdd4f42494e,
title = "Prospective native coronary artery stenosis treated with sirolimus-eluting stent (ONASSIS) registry - Acute results and mid-term outcomes: A single-center experience",
abstract = "Background. Encouraging results with the use of the sirolimus-eluting stent (SES) have been recently presented in several multicenter trials. In the present study, the short-and mid-term clinical outcomes of the SES in everyday clinical practice of interventional cardiology were compared with a strategy using conventional bare metal stents. Methods. In a total of 530 consecutive patients (males 86{\%}, mean age 61 ± 10 years) who had been treated with a SES were compared with a control group of 398 patients (males 87{\%}, mean age 59 ± 11 years) treated with a bare metal stent before the use of SES. In-hospital results and clinical outcomes during follow-up (11.22 ± 3.4 versus 11.41 ± 3.1 months) were obtained. Results. Patients treated with SES had more risk factors for coronary artery disease or multivessel disease compared to those with treated bare metal stent. The clinical success rate was 99.6{\%} in the SES group and 98.5{\%} in the bare metal stent group (p = ns), and non-Q-wave myocardial infarction (MI) occurred in 5.7{\%} and 4.0{\%} of patients, respectively. The incidence of death or MI during follow-up was not different (1.1{\%} versus 1.3{\%} and 0.8{\%} versus 1.8{\%}; p = ns). Percutaneous or surgical revascularization for target lesion restenosis was required in 2.1{\%} of patients treated with SES and in 10.1{\%} of those with bare metal stents (p < 0.001), and the event-free survival from death, cerebrovascular accident, MI or any percutaneous or surgical revascularization was 93.13{\%} and 83.63{\%}, respectively (p < 0.01). Conclusions. The implantation of the SES is associated with excellent in-hospital and mid-term results, mainly because of dramatic reductions in the need for repeat revascularization, despite a higher risk factor profile and more complex lesion characteristics.",
author = "Vassilis Voudris and Elias Alexopoulos and Panagiotis Karyofillis and John Malakos and Athanasios Manginas and Constantinos Spargias and Gregory Pavlides and Sotirios Patsilinakos and Alexandros Anyfantakis and Cokkinos, {Dennis V.}",
year = "2005",
month = "8",
day = "1",
language = "English (US)",
volume = "17",
pages = "401--405",
journal = "Journal of Invasive Cardiology",
issn = "1042-3931",
publisher = "HMP Communications",
number = "8",

}

TY - JOUR

T1 - Prospective native coronary artery stenosis treated with sirolimus-eluting stent (ONASSIS) registry - Acute results and mid-term outcomes

T2 - A single-center experience

AU - Voudris, Vassilis

AU - Alexopoulos, Elias

AU - Karyofillis, Panagiotis

AU - Malakos, John

AU - Manginas, Athanasios

AU - Spargias, Constantinos

AU - Pavlides, Gregory

AU - Patsilinakos, Sotirios

AU - Anyfantakis, Alexandros

AU - Cokkinos, Dennis V.

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Background. Encouraging results with the use of the sirolimus-eluting stent (SES) have been recently presented in several multicenter trials. In the present study, the short-and mid-term clinical outcomes of the SES in everyday clinical practice of interventional cardiology were compared with a strategy using conventional bare metal stents. Methods. In a total of 530 consecutive patients (males 86%, mean age 61 ± 10 years) who had been treated with a SES were compared with a control group of 398 patients (males 87%, mean age 59 ± 11 years) treated with a bare metal stent before the use of SES. In-hospital results and clinical outcomes during follow-up (11.22 ± 3.4 versus 11.41 ± 3.1 months) were obtained. Results. Patients treated with SES had more risk factors for coronary artery disease or multivessel disease compared to those with treated bare metal stent. The clinical success rate was 99.6% in the SES group and 98.5% in the bare metal stent group (p = ns), and non-Q-wave myocardial infarction (MI) occurred in 5.7% and 4.0% of patients, respectively. The incidence of death or MI during follow-up was not different (1.1% versus 1.3% and 0.8% versus 1.8%; p = ns). Percutaneous or surgical revascularization for target lesion restenosis was required in 2.1% of patients treated with SES and in 10.1% of those with bare metal stents (p < 0.001), and the event-free survival from death, cerebrovascular accident, MI or any percutaneous or surgical revascularization was 93.13% and 83.63%, respectively (p < 0.01). Conclusions. The implantation of the SES is associated with excellent in-hospital and mid-term results, mainly because of dramatic reductions in the need for repeat revascularization, despite a higher risk factor profile and more complex lesion characteristics.

AB - Background. Encouraging results with the use of the sirolimus-eluting stent (SES) have been recently presented in several multicenter trials. In the present study, the short-and mid-term clinical outcomes of the SES in everyday clinical practice of interventional cardiology were compared with a strategy using conventional bare metal stents. Methods. In a total of 530 consecutive patients (males 86%, mean age 61 ± 10 years) who had been treated with a SES were compared with a control group of 398 patients (males 87%, mean age 59 ± 11 years) treated with a bare metal stent before the use of SES. In-hospital results and clinical outcomes during follow-up (11.22 ± 3.4 versus 11.41 ± 3.1 months) were obtained. Results. Patients treated with SES had more risk factors for coronary artery disease or multivessel disease compared to those with treated bare metal stent. The clinical success rate was 99.6% in the SES group and 98.5% in the bare metal stent group (p = ns), and non-Q-wave myocardial infarction (MI) occurred in 5.7% and 4.0% of patients, respectively. The incidence of death or MI during follow-up was not different (1.1% versus 1.3% and 0.8% versus 1.8%; p = ns). Percutaneous or surgical revascularization for target lesion restenosis was required in 2.1% of patients treated with SES and in 10.1% of those with bare metal stents (p < 0.001), and the event-free survival from death, cerebrovascular accident, MI or any percutaneous or surgical revascularization was 93.13% and 83.63%, respectively (p < 0.01). Conclusions. The implantation of the SES is associated with excellent in-hospital and mid-term results, mainly because of dramatic reductions in the need for repeat revascularization, despite a higher risk factor profile and more complex lesion characteristics.

UR - http://www.scopus.com/inward/record.url?scp=25144498734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25144498734&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 401

EP - 405

JO - Journal of Invasive Cardiology

JF - Journal of Invasive Cardiology

SN - 1042-3931

IS - 8

ER -